BridgeBio Pharma Net Income 2018-2024 | BBIO
BridgeBio Pharma annual/quarterly net income history and growth rate from 2018 to 2024. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
- BridgeBio Pharma net income for the quarter ending September 30, 2024 was $-0.162B, a 8.45% decline year-over-year.
- BridgeBio Pharma net income for the twelve months ending September 30, 2024 was $-0.439B, a 28.37% decline year-over-year.
- BridgeBio Pharma annual net income for 2023 was $-0.643B, a 33.67% increase from 2022.
- BridgeBio Pharma annual net income for 2022 was $-0.481B, a 14.46% decline from 2021.
- BridgeBio Pharma annual net income for 2021 was $-0.563B, a 25.36% increase from 2020.
BridgeBio Pharma Annual Net Income
(Millions of US $) |
| 2023 |
$-643 |
| 2022 |
$-481 |
| 2021 |
$-563 |
| 2020 |
$-449 |
| 2019 |
$-261 |
| 2018 |
$-131 |
| 2017 |
$-31 |
BridgeBio Pharma Quarterly Net Income
(Millions of US $) |
| 2024-09-30 |
$-162 |
| 2024-06-30 |
$-73 |
| 2024-03-31 |
$-35 |
| 2023-12-31 |
$-168 |
| 2023-09-30 |
$-177 |
| 2023-06-30 |
$-158 |
| 2023-03-31 |
$-140 |
| 2022-12-31 |
$-138 |
| 2022-09-30 |
$-137 |
| 2022-06-30 |
$-10 |
| 2022-03-31 |
$-196 |
| 2021-12-31 |
$-147 |
| 2021-09-30 |
$-156 |
| 2021-06-30 |
$-96 |
| 2021-03-31 |
$-163 |
| 2020-12-31 |
$-120 |
| 2020-09-30 |
$-116 |
| 2020-06-30 |
$-121 |
| 2020-03-31 |
$-92 |
| 2019-12-31 |
$-73 |
| 2019-09-30 |
$-60 |
| 2019-06-30 |
$-66 |
| 2019-03-31 |
$-61 |
| 2018-12-31 |
|
| 2018-09-30 |
$-31 |
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$6.773B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
